Dendreon's announcement that its Phase 3 prostate cancer vaccine Provenge "met its primary endpoint of improving overall survival" in the crucial IMPACT trial will likely have the prostate cancer ...

A couple of years ago, Dendreon sold off a manufacturing plant to Novartis ($NVS) for $40 million-plus to raise some quick cash. Now, someone can pick up its two ...

Add Yahoo as a preferred source to see more of our stories on Google. By Natalie Grover (Reuters) - Dendreon Corp filed for Chapter 11 bankruptcy protection after sales of the world's first cancer ...

Three years after the controversial Provenge prostate cancer vaccine was approved by the FDA, Dendreon has finally released a television ad campaign. Will this be a case of 'too little, too late?' or ...

Dendreon is readying a $5 million-per-quarter “targeted” DTC advertising campaign as the company seeks to goose sluggish growth in sales of its prostate cancer treatment Provenge. Said EVP, global ...

With an EU approval for Provenge in the bag, the question now turns to whether the prostate cancer therapy will sell. Although we don't believe in timing the market or panicking over market movements, ...

Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

NEW YORK (AP) -- Shares of Dendreon Corp. tumbled to their lowest price in four years Friday after the company again lowered its expectations for sales of its prostate cancer therapy Provenge. THE ...

Dendreon, which last summer changed ownership for a third time in as many years, signaled its faith in prostate drug Provenge by signing a lease extension for its Seal Beach, California, manufacturing ...

In the video below, Fool analysts David Williamson and Max Macaluso discuss drugmaker Dendreon as a possible takeover target in 2013. While hope of a buyout has diminished as Dendreon's struggles ...